Alcator develops its products through formulation or reprofiling existing compounds with established clinical activity and systemic safety. It currently has eight marketed pharmaceutical products in the portfolio.
Beringea partner Stephane Mery said, “Since Beringea’s initial investment, Altacor has exhibited continued growth and we are delighted to have worked with such an exceptional management team.
“Esperante’s purchase of Altacor will enable the company to continue its path towards becoming a European leader in the ophthalmology market.”
Beringea’s recent deals include an investment in online designer glasses store MyOptique Group as part of its £16m round.
Copyright © 2014 AltAssets